drugset / Trial / NCT01333605

IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma

NCT01333605

Phase 2 Unknown 43 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

The aim of study is to prove IGEV regimen followed by autologous stem cell transplantation as salvage treatment in patients with refractory or relapsed Hodgkin lymphoma is effective.

Timeline

Start
2011-04
Primary completion
2014-04
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject 2-MERCAPTOETHANESULFONIC ACID Small molecule 400 mg
Subject Gemcitabine Small molecule 800 mg/m2
Subject Ifosfamide Small molecule 1200 mg/m2
Subject Prednisone Other / unclassified 100 mg
Subject Vinorelbine Small molecule 20 mg/m2

Indications